Pharma BD Deal Intelligence
Roche got the ECL technology it needed for its Elecsys immunoassay franchise, but the IGEN IP tail generated two decades of costly litigation, including a $137.3M jury verdict in 2019 that is still unresolved.
Full analysis, sources & comparables →Roche escaped IGEN damages but lost ECL rights under the 1992 license, forcing Roche to either lose the $400M+ Elecsys business or buy IGEN outright - the…
IGEN's 8-K announces definitive agreements resolving the Roche ORIGEN dispute under which Roche acquires IGEN, presenting the transaction favorably as a…
Industry analysis framed Roche's IGEN acquisition as silencing a long-running license dispute that produced a $505M jury verdict; deal structure used spin-off…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Roche acquired IGEN International for approximately $1.4 billion ($47.25 per share plus a share in the newly spun-off BioVeris), securing perpetual worldwide rights to IGEN's electrochemiluminescence (ECL) technology underpinning its Elecsys diagnostics line. The transaction resolved a long-running ECL license dispute that had produced a major jury verdict against Roche. Announced July 2003 and closed in mid-February 2004.
Roche got the ECL technology it needed for its Elecsys immunoassay franchise, but the IGEN IP tail generated two decades of costly litigation, including a $137.3M jury verdict in 2019 that is still unresolved.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / IGEN International Inc. (this deal) | 2003 | $1.4B | 68 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2003 deals · Roche Holding AG deals